Flexible Dosing of Abrocitinib in Patients With Moderate-to-Severe Atopic Dermatitis: Initial Results From the Real-World–Simulating Expanded Access Protocol Study, JADE REAL. SKIN The Journal of Cutaneous Medicine, [S. l.], v. 9, n. 6, p. s618, 2025. DOI: 10.25251/t4rkzz84. Disponível em: https://skin.dermsquared.com/skin/article/view/3822. Acesso em: 26 may. 2026.